BioAcyl Corp |
![]() |
| Resource type: Journal Article DOI: 10.1016/j.cell.2022.01.018 ID no. (ISBN etc.): 0092-8674, 1097-4172 BibTeX citation key: 2022 View all bibliographic details |
Categories: BioAcyl Corp Subcategories: COVID-19 Vaccines Creators: Arunachalam, Beach, Boyd, Chang, Charville, Chinthrajah, Colburg, Costales, Dashdorj, Dashdorj, Davis, Gao, Haraguchi, Hoh, Lee, Li, Liu, Mallajosyula, Manohar, Monroe, Nadeau, Natkunam, Nielsen, Parsons, Pinsky, Pulendran, Röltgen, Serrano, Shah, Shoura, Sigal, Silva, Sindher, Solis, Troxell, Wang, Wilbur, Wirz, Wohlstadter, Yang, Younes, Zaslavsky, Zhao Collection: Cell |
Views: 2/287
|
| Abstract |
|
{textless}h2{textgreater}Summary{textless}/h2{textgreater}{textless}p{textgreater}During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been deployed globally. We investigated whether antibodies stimulated by mRNA vaccination (BNT162b2), including 3$^{textrm{rd}}$ dose boosting, differ from those generated by infection or adenoviral (ChAdOx1-S and Gam-COVID-Vac) or inactivated viral (BBIBP-CorV) vaccines. We analyzed human lymph nodes after infection or mRNA vaccination for correlates of serological differences. Antibody breadth against viral variants is less after infection compared to all vaccines evaluated, but improves over several months. Viral variant infection elicits variant-specific antibodies, but prior mRNA vaccination imprints serological responses toward Wuhan-Hu-1 rather than variant antigens. In contrast to disrupted germinal centers (GCs) in lymph nodes during infection, mRNA vaccination stimulates robust GCs containing vaccine mRNA and spike antigen up to 8 weeks post-vaccination in some cases. SARS-CoV-2 antibody specificity, breadth and maturation are affected by imprinting from exposure history, and distinct histological and antigenic contexts in infection compared to vaccination.{textless}/p{textgreater}
|
| Notes |
|
Publisher: Elsevier
|